Evidence map›Paper›PMID 35957970›Full record

ArticleHealth science reports2022

Evaluation of a novel SARS-CoV-2 rapid antigenic test diagnostic value in respiratory samples; is the reported test accuracy similar to values in the real-world? A cross-sectional study.

Hossein Hatami, AhmadReza Rezaeian

Open access · goldAbstract read
In one paragraph

Article in Health science reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.1field-weighted citation impact, top 57% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Hossein HatamiDepartment of Public Health and Safety School of Public Health and Environmental and Occupational Hazard Control Research Center, Shahid Beheshti University of Medical Sciences Tehran Iran.
AhmadReza RezaeianFaculty of Medicine Shahid Beheshti University of Medical Sciences Tehran Iran.ORCID 0000-0001-9642-3128
Shahid Beheshti University of Medical Sciences · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background and Aims: Although reverse transcription-polymerase chain reaction (RT-PCR) assay was introduced as the gold standard to detect SARS-CoV-2, the method was known to be time-consuming besides the requirement for an equipped laboratory. This survey aims to investigate a novel SARS-CoV-2 antigen test as a diagnostic tool in COVID-19 patients to overcome these limitations in addition to evaluating COVID-19 population characteristics. Methods: A retrospective cross-sectional study was carried out during the first semester of 2021, and about 1070 nasopharyngeal samples were collected to compare the E-Health Barakat Company SARS-CoV-2 antigen rapid test results with RT-PCR reports as the reference method. Results: Totally 537 participants were included in this study for employing RT-PCR and the antigen test sequentially. The novel antigen rapid test sensitivity is considered 21.09% in the real world, though 81% in the manufacturer's instruction has been mentioned. Moreover, the most revealed manifestations were found respiratory symptoms and fatigue sensations. Conclusion: This study is the first one on evaluating the SARS-CoV-2 antigen test in our country. Although the novel antigen assay was found quick and easy to perform, the test performance was very disappointing. The extensive false-negative results made it an inappropriate candidate for mass screening.

Indexed as

antigen testCOVID‐19 symptomsdiagnostic ValueRT‐PCRSARS‐CoV‐2

Identifiers

PMID35957970
PMCPMC9364431
OpenAlexW4291709691

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.